Background: Obesity is a chronic complex disease with an increasing prevalence around the world. Prospective studies in adult cohorts are needed to provide information about predictors of new-onset overweight/obesity on population-based levels. The aim of this study was to identify factors associated with the risk of an adult individual become overweight/obese after 13 years of follow-up.
Methods: Second phase of an observational population-based prospective cohort study in a small town in the Midwest region of Brazil. A representative sample of the adult population (≥18 years) was assessed in 2002 (phase 1). Anthropometric, sociodemographic, dietary intake and lifestyle data were collected. After 13 years of follow-up (2015), the same variables were re-evaluated (phase 2). New-onset overweight/obesity was the outcome variable.
Results: A total of 685 subjects were included with a mean age in phase 1 of 42.7 ± 13.8 years and 56.1 ± 13.8 years in phase 2, the mean follow-up time was 13.2 years and female sex counted for 66.3% of the sample. Total weight gain was 5.9 ± 10.2 Kg, body mass index increased 2.6 ± 3.8 Kg/m and waist circumference (WC) values increased 8.0 ± 10.5 cm. The prevalence of overweight/obesity went from 49.1% in phase 1 to 69.8% in phase 2 (p < 0.001). The factors associated with a decreased risk of new-onset overweight/obesity were ages between 50 and 64 (RR 0.40; CI 0.24-0.67 - p = 0.001) and ≥65 years (RR 0.15; CI 0.06-0.35 - p < 0.001), being part of the second quartile of fat consumption (RR 0.59; CI 0.35-0.97 - p = 0.041), no alcohol consumption (RR 0.59; CI 0.37-0.93 - p = 0.024) and smoking (RR 0.58; CI 0.39-0.86 - p = 0,007) in phase 1.
Conclusions: We identified in thirteen years of follow-up that older ages, a moderate fat consumption compared to low consumption, no alcohol consumption and smoking habit were related to a decreased risk of new-onset overweight/obesity. Obesity prevention actions must focus on subjects at younger ages and include policies to reduce alcohol consumption.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769518 | PMC |
| http://dx.doi.org/10.1186/s12937-018-0320-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prospective associations of adolescent obesity phenotypes with self-reported polycystic ovary syndrome diagnosis in young adulthood.
Hum Reprod
January 2025
Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.
Study Question: Are empirically derived adolescent overweight/obesity phenotypes differentially associated with polycystic ovary syndrome (PCOS) in young adulthood?
Summary Answer: Self-reported PCOS diagnosis risk in young adulthood varied by empirically derived adolescent overweight/obesity phenotypes, with the highest risk observed among those in the 'mothers with obesity' and 'early puberty' phenotypes.
What Is Known Already: Overweight and obesity during puberty are postulated to promote the development of PCOS. Much of the prior literature in this area is cross-sectional and defines weight status based solely on BMI, yet emerging research suggests that not all people with overweight/obesity have the same risk for chronic health conditions, including PCOS.
Effect of an intensive lifestyle intervention on cystatin C-based kidney function in adults with overweight and obesity: From the PREDIMED-Plus trial.
J Intern Med
December 2024
Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Málaga, Spain.
Background: Large-scale trials evaluating a multicomponent lifestyle intervention aimed at weight loss on kidney function are lacking.
Methods: This was a post hoc analysis of the "PREvención con DIeta MEDiterránea-Plus" (PREDIMED-Plus) randomized controlled trial, including patients with overweight/obesity and metabolic syndrome, measured cystatin C and creatinine. Participants were randomly assigned (1:1) to an intensive weight loss lifestyle intervention (intervention group [IG]) consisting of an energy-restricted Mediterranean diet (MedDiet), physical activity promotion and behavioral support, or a control group (CG) receiving ad libitum MedDiet recommendations.
Association of hypertension and long-term blood pressure changes with new-onset diabetes in the elderly: A 10-year cohort study.
Diabetes Obes Metab
January 2025
Department of Medical College, Jiangsu Vocational College of Medicine, Yancheng, China.
Aim: To explore the correlation between new-onset diabetes (NOD), hypertension and blood pressure management among elderly individuals in China.
Materials And Methods: A cohort analysis involved 1380 participants aged 60 years or older, initially free of diabetes in 2008, from the Chinese Longitudinal Healthy Longevity Survey. Follow-up assessments occurred every 2-3 years.
High-density lipoprotein cholesterol trajectory and new-onset metabolic dysfunction-associated fatty liver disease incidence: a longitudinal study.
Diabetol Metab Syndr
September 2024
Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.
Article Synopsis
- The study investigates how changes in high-density lipoprotein cholesterol (HDL-C) levels are linked to the risk of developing metabolic dysfunction-associated fatty liver disease (MAFLD).
- Researchers analyzed data from 1507 participants to identify different patterns of HDL-C levels and their correlation with the onset of MAFLD over time.
- Results indicated that individuals with persistently low HDL-C levels had a significantly higher risk of developing MAFLD, highlighting the importance of monitoring HDL-C as a preventive measure.
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors.
JACC Heart Fail
November 2024
Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA. Electronic address:
Article Synopsis
- - The study explores the additional benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for patients with obesity, type 2 diabetes, and heart failure with preserved ejection fraction (HFpEF) who are already on sodium-glucose cotransporter 2 inhibitors (SGLT2i).
- - Researchers analyzed data from over 7,000 patients and found that those taking both GLP-1 RA and SGLT2i had significantly lower risks of heart failure exacerbations and other health issues compared to those on SGLT2i alone.
- - While the combination therapy showed many benefits, it also had an increased risk of diabetic retinopathy, indicating the need for
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!